美国儿童非感染性葡萄膜炎的发病率、患病率及临床关联:TriNetX数据库研究
年发病率从22/10万升至33/10万,患病率从106/10万升至226/10万;青光眼(8.8%)和白内障(6.9%)是最常见眼部并发症,后葡萄膜炎盲与低视力率最高(13.4%)。
要点
- 儿童葡萄膜炎以女性为主(男性54.6%),中位年龄11岁,前葡萄膜炎占73.6%。
- 2016–2025年,年发病率22→33/10万,患病率106→226/10万,均呈上升趋势。
- 泼尼松(13.6%)和甲氨蝶呤(13.1%)最常用,抗代谢药类最常处方(15.6%)。
核心结论
- 过去十年美国儿童非感染性葡萄膜炎的发病率和患病率均上升。
- 前葡萄膜炎占主导,但眼部并发症和治疗强度集中于中间葡萄膜炎,视力丧失集中于后葡萄膜炎。
研究设计与样本
- 回顾性发病率和患病率研究,基于TriNetX美国协作网络2016–2025年数据。
- 纳入17岁及以下葡萄膜炎患者,按SUN分类分为前、中间、后和全葡萄膜炎亚型。
主要发现
- 青光眼2509例(8.8%;95%CI 8.5–9.1)和白内障1962例(6.9%;95%CI 6.6–7.2)为最常见眼部并发症;后葡萄膜炎盲与低视力397例(13.4%;95%CI 12.2–14.6)。
- 泼尼松3979例(13.6%)和甲氨蝶呤3854例(13.1%)最常处方,抗代谢药类4568例(15.6%)最常见。
- 幼年特发性关节炎3038例(10.4%)和肾小管间质性肾炎伴葡萄膜炎450例(1.5%)为最常见特定系统关联。
关键数值与推荐
- 葡萄膜炎总体比例0.10%,男性比例54.6%(95%CI 54.0–55.2)。
- 年发病率22→33/10万,患病率106→226/10万(2016–2025年)。
- 青光眼8.8%(95%CI 8.5–9.1),白内障6.9%(95%CI 6.6–7.2)。
- 后葡萄膜炎盲与低视力13.4%(95%CI 12.2–14.6)。
- 泼尼松13.6%,甲氨蝶呤13.1%,抗代谢药类15.6%;幼年特发性关节炎10.4%,肾小管间质性肾炎伴葡萄膜炎1.5%。
临床怎么用
- 临床应关注儿童葡萄膜炎发病率上升趋势,前葡萄膜炎最常见但需警惕中间和后葡萄膜炎的并发症风险。
- 对中间葡萄膜炎加强并发症监测和治疗强度管理,对后葡萄膜炎重点防范视力丧失。
- 系统筛查应关注幼年特发性关节炎和肾小管间质性肾炎伴葡萄膜炎等相关系统疾病。
局限性
- 回顾性数据库研究,依赖ICD-10-CM、RxNorm和HCPCS编码识别病例,可能存在编码偏倚。
- 发病率上升可能反映真实疾病增加或检测水平提高,需前瞻性研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the incidence, prevalence, demographics, anatomic subtypes, ocular complications, associated systemic diseases, and immunosuppressive treatment patterns of noninfectious pediatric uveitis in the United States using the TriNetX database. DESIGN: Retrospective incidence and prevalence study. SUBJECTS: Patients aged 17 years or younger with uveitis in the TriNetX US Collaborative Network between 2016 and 2025, stratified into anterior, intermediate, posterior, and panuveitis subtypes according to the Standardization of Uveitis Nomenclature classification. METHODS: Demographic characteristics, ocular complications, associated systemic inflammatory diseases, and systemic immunosuppressive medications were identified using International Classification of Diseases, Tenth Revision, Clinical Modification, RxNorm, and Healthcare Common Procedure Coding System codes. Incidence and prevalence were calculated per 100 000 persons, annually and cumulatively, overall and by subtype. Proportions are reported with 95% confidence intervals (CIs) constructed using Wilson score intervals. MAIN OUTCOME MEASURES: Annual and cumulative incidence and prevalence of pediatric uveitis and its subtypes, demographic distribution, rates of ocular complications, associated systemic diseases, and immunosuppressive medication use. RESULTS: Of 30 729 490 children, 30 533 (0.10%) had uveitis. Median age was 11 years (interquartile range, 8 years); 16 671 (54.6%; 95% CI, 54.0-55.2) were male. Anterior uveitis was the most common subtype (22 481; 73.6%). From 2016 to 2025, annual incidence rose from 22 to 33 per 100 000 persons and prevalence from 106 to 226 per 100 000 persons. Glaucoma (2509; 8.8%; 95% CI, 8.5-9.1) and cataract (1962; 6.9%; 95% CI, 6.6-7.2) were the most common ocular complications; posterior uveitis had the highest rate of blindness and low vision (397; 13.4%; 95% CI, 12.2-14.6). Prednisone (3979; 13.6%) and methotrexate (3854; 13.1%) were most frequently prescribed, and antimetabolites were the most common class (4568; 15.6%). Juvenile idiopathic arthritis (3038; 10.4%) and tubulointerstitial nephritis and uveitis (450; 1.5%) were the most frequent discrete systemic associations. CONCLUSIONS: The incidence and prevalence of pediatric uveitis increased over the past decade. Anterior uveitis predominated, whereas ocular morbidity and treatment intensity concentrated in intermediate uveitis and vision loss in posterior uveitis. Juvenile idiopathic arthritis and tubulointerstitial nephritis and uveitis were frequent associations. Prospective studies should determine whether rising rates reflect a true increase in disease or improved detection.
引用
- Nijim W, Pham NV, Liu R, et al. Incidence, Prevalence, and Clinical Associations of Noninfectious Pediatric Uveitis in the United States: A TriNetX Database Study. Am J Ophthalmol. 2026. PMID: 42762946. doi:10.1016/j.ajo.2026.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。